^
BIOMARKER:

TP53 wild-type

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
TP53 wild-type
Small Lymphocytic Lymphoma
PCR
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
FCR
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
chlorambucil
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
CD20 inhibitor
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
TP53 wild-type
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive: A2 - Guideline
TP53 wild-type
CLL
zanubrutinib
Sensitive: A2 - Guideline
TP53 wild-type
AML
RO5503781
Resistant: B - Late Trials
TP53 wild-type
Lymphoma
ALRN-6924
Sensitive: C2 – Inclusion Criteria
TP53 wild-type
Solid Tumor
ALRN-6924
Sensitive: C2 – Inclusion Criteria
TP53 wild-type
Solid Tumor
KRT-232
Sensitive: C2 – Inclusion Criteria
TP53 wild-type
AML
HDM201
Sensitive: C3 – Early Trials
TP53 wild-type
Solid Tumor
HDM201
Sensitive: C3 – Early Trials
TP53 wild-type
Liposarcoma
MK-8242
Sensitive: C3 – Early Trials
TP53 wild-type
Solid Tumor
MK-8242
Sensitive: C3 – Early Trials
TP53 wild-type
Multiple Myeloma
KRT-232
Sensitive: C3 – Early Trials
TP53 wild-type
Liposarcoma
HDM201
Sensitive: C3 – Early Trials
TP53 wild-type
Breast Cancer
selinexor
Sensitive: D – Preclinical
TP53 wild-type
Breast Cancer
chidamide
Sensitive: D – Preclinical
TP53 wild-type
AML
thioureidobutyronitrile
Sensitive: D – Preclinical
TP53 wild-type
Multiple Myeloma
APG-115
Sensitive: D – Preclinical
TP53 wild-type
Multiple Myeloma
bortezomib + APG-115
Sensitive: D – Preclinical
TP53 wild-type
Breast Cancer
APG-115 + KRT-232
Sensitive: D – Preclinical
TP53 wild-type
Breast Cancer
chidamide
Sensitive: D – Preclinical